Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An IL-17-DUOX2 axis controls gastrointestinal colonization by Candida albicans.
Kakade P, Burgueno JF, Sircaik S, Ponde N, Li J, Ene IV, Kim J, Liang SH, Yunker R, Akiba Y, Vaishnava S, Kaunitz JD, Way SS, Koh AY, Gaffen S, Abreu MT, Bennett RJ. Kakade P, et al. Among authors: ponde n. bioRxiv [Preprint]. 2024 Aug 19:2024.08.16.608271. doi: 10.1101/2024.08.16.608271. bioRxiv. 2024. PMID: 39229022 Free PMC article. Preprint.
IκBζ is an essential mediator of immunity to oropharyngeal candidiasis.
Taylor TC, Coleman BM, Arunkumar SP, Dey I, Dillon JT, Ponde NO, Poholek AC, Schwartz DM, McGeachy MJ, Conti HR, Gaffen SL. Taylor TC, et al. Among authors: ponde no. Cell Host Microbe. 2023 Oct 11;31(10):1700-1713.e4. doi: 10.1016/j.chom.2023.08.016. Epub 2023 Sep 18. Cell Host Microbe. 2023. PMID: 37725983 Free PMC article.
EGR1 regulates oral epithelial cell responses to Candida albicans via the EGFR- ERK1/2 pathway.
Dickenson RE, Pellon A, Ponde NO, Hepworth O, Daniels Gatward LF, Naglik JR, Moyes DL. Dickenson RE, et al. Among authors: ponde no. bioRxiv [Preprint]. 2023 Apr 3:2023.03.31.535186. doi: 10.1101/2023.03.31.535186. bioRxiv. 2023. Update in: Virulence. 2024 Dec;15(1):2435374. doi: 10.1080/21505594.2024.2435374. PMID: 37066428 Free PMC article. Updated. Preprint.
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T; APHINITY Steering Committee and Investigators. de Azambuja E, et al. Among authors: ponde n. ESMO Open. 2023 Feb;8(1):100772. doi: 10.1016/j.esmoop.2022.100772. Epub 2023 Jan 19. ESMO Open. 2023. PMID: 36681013 Free PMC article. Clinical Trial.
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M. Agostinetto E, et al. Among authors: ponde n. NPJ Breast Cancer. 2022 Jul 20;8(1):87. doi: 10.1038/s41523-022-00452-8. NPJ Breast Cancer. 2022. PMID: 35859079 Free PMC article.
69 results